Clinical Trial Update: Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase [Phase 3]

View source ↗

Summary

Phase 3 trial of exebacase for direct lysis of Staphylococcus aureus showing terminated status with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Staphylococcus Aureus Bacteremia
• Staphylococcus Aureus Endocarditis

Drugs mentioned

• exebacase (exebacase)

Snippet

Sponsor: ContraFect | Conditions: Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis | Phase 3 | Status: TERMINATED | Results posted: 2023-10-18